Loading clinical trials...
Loading clinical trials...
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Conditions
Interventions
rodatristat ethyl 300 mg tablet BID
rodatristat ethyl 600 mg BID
+1 more
Locations
64
United States
Arizona Pulmonary Specialists
Phoenix, Arizona, United States
University of California San Diego Health Sciences
La Jolla, California, United States
VA Greater LA Healthcare System/UCLA
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
UC Davis Medical Center
Sacramento, California, United States
Jeffrey S. Sager, MD Medical Corporation
Santa Barbara, California, United States
Start Date
March 15, 2021
Primary Completion Date
June 5, 2023
Completion Date
August 28, 2023
Last Updated
June 4, 2025
NCT07218029
NCT07120789
NCT06649110
NCT04778046
NCT06481852
NCT06477640
Lead Sponsor
Altavant Sciences GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions